New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
07:38 EDTLPTNLpath's Lpathomab to be studied for efficacy in traumatic brain injury
Lpath and scientists from the Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research, have initiated a study that is the focus of a collaborative research agreement involving the use of Lpathomab, an antibody to lysophosphatidic acid, in the treatment of brain injury induced by blast overpressure. There are currently no FDA-approved drug treatments for any form of TBI. Lpath is currently conducting IND-enabling studies for Lpathomab and intends to enter Phase 1 clinical trials in early 2015 for neuropathic pain and neurotrauma.
News For LPTN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for LPTN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use